Učitavanje...
Somatostatin receptor radionuclide therapy in neuroendocrine tumors
Peptide receptor radionuclide therapy (PRRT) using (177)Lu-DOTATATE has been approved for the treatment of gastroenteropancreatic NETs. An understanding of benefits and risks is important for the appropriate implementation of this therapy. This review summarizes study data supporting the use of radi...
Spremljeno u:
| Izdano u: | Endocr Relat Cancer |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8118168/ https://ncbi.nlm.nih.gov/pubmed/33608483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-20-0360 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|